Cell therapy updates: expanded partnership to manufacture CRISPR CAR-T for solid tumors
Discover the latest breakthroughs in cancer cell therapies in this edition of RegMedNet’s Cell Therapy Weekly.
The past week saw advancements in cell therapy manufacturing and development. Cellares (CA, USA) expanded its partnership with the University of Wisconsin School of Medicine and Public Health (WI, USA) to support clinical production and regulatory advancement of a CRISPR-edited GD2 CAR-T investigational therapy for solid tumors.
Meanwhile, Johnson & Johnson announced a US$1 billion investment to build a new cell therapy manufacturing facility, strengthening its capacity for next-generation cell therapies targeting cancer, immune-mediated and neurological diseases.